T. Geldart

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

Thomas Powles, Matthew Wheater, Omar Din et al. · European Urology · 2015 · 100 citations

Medicine, Nephrology, Oncology +14

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 81 citations · Full text

Medicine, Oncology, Pharmacology +11

Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer—a necessary risk?

Marjorie Harvey, T. Geldart, Ryan Duell et al. · Annals of Oncology · 2002 · 55 citations · Full text

Medicine, Oncology, Radiology +16

Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

Peter Johnson, T. Geldart, P. Fumoleau et al. · Investigational New Drugs · 2005 · 41 citations

Medicine, Pharmacokinetics, Pharmacology +6